Under certain conditions, there is a risk for a false negative result.
BioMerieux SA
Software anomaly - Under certain conditions, unwanted alterations to results could be applied when using the BCI Connect scripting feature.
Data loggers showed that one shipment to the United States experienced low temperatures that may impact performance of this product.
Invalid calibration with low calibrator S1 while using the product.
A shipment to Guadeloupe suffered a temperature excursions up to 47.8ÂżC, exceeding the acceptable limits. After detection of the issue, Global Supply Chain QA asked the bioMÂżrieux distributor in Guadeloupe to put products in quarantine in July 2017; After several reminders, the distributor informed in November 2017 that products were delivered to customers.
A shipment to Guadeloupe suffered a temperature excursions up to 47.8ÂżC, exceeding the acceptable limits. After detection of the issue, Global Supply Chain QA asked the bioMÂżrieux distributor in Guadeloupe to put products in quarantine in July 2017; After several reminders, the distributor informed in November 2017 that products were delivered to customers.
A shipment to Guadeloupe suffered a temperature excursions up to 47.8ÂżC, exceeding the acceptable limits. After detection of the issue, Global Supply Chain QA asked the bioMÂżrieux distributor in Guadeloupe to put products in quarantine in July 2017; After several reminders, the distributor informed in November 2017 that products were delivered to customers.
A shipment to Guadeloupe suffered a temperature excursions up to 47.8ÂżC, exceeding the acceptable limits. After detection of the issue, Global Supply Chain QA asked the bioMÂżrieux distributor in Guadeloupe to put products in quarantine in July 2017; After several reminders, the distributor informed in November 2017 that products were delivered to customers.
A shipment to Guadeloupe suffered a temperature excursions up to 47.8ÂżC, exceeding the acceptable limits. After detection of the issue, Global Supply Chain QA asked the bioMÂżrieux distributor in Guadeloupe to put products in quarantine in July 2017; After several reminders, the distributor informed in November 2017 that products were delivered to customers.
A shipment to Guadeloupe suffered a temperature excursions up to 47.8ÂżC, exceeding the acceptable limits. After detection of the issue, Global Supply Chain QA asked the bioMÂżrieux distributor in Guadeloupe to put products in quarantine in July 2017; After several reminders, the distributor informed in November 2017 that products were delivered to customers.
A shipment to Guadeloupe suffered a temperature excursions up to 47.8ÂżC, exceeding the acceptable limits. After detection of the issue, Global Supply Chain QA asked the bioMÂżrieux distributor in Guadeloupe to put products in quarantine in July 2017; After several reminders, the distributor informed in November 2017 that products were delivered to customers.
A shipment to Guadeloupe suffered a temperature excursions up to 47.8ÂżC, exceeding the acceptable limits. After detection of the issue, Global Supply Chain QA asked the bioMÂżrieux distributor in Guadeloupe to put products in quarantine in July 2017; After several reminders, the distributor informed in November 2017 that products were delivered to customers.
A shipment to Guadeloupe suffered a temperature excursions up to 47.8ÂżC, exceeding the acceptable limits. After detection of the issue, Global Supply Chain QA asked the bioMÂżrieux distributor in Guadeloupe to put products in quarantine in July 2017; After several reminders, the distributor informed in November 2017 that products were delivered to customers.
QC failures (MIC out of range high) for S.aureus ATCC 29213 strain on ETEST OX 256 (OXACILLIN) Foam packaging (Ref. 520558, 520518) reported. The product behavior could lead to False Resistant results.
QC failures (MIC out of range high) for S.aureus ATCC 29213 strain on ETEST OX 256 (OXACILLIN) Foam packaging (Ref. 520558, 520518) reported. The product behavior could lead to False Resistant results.
Elute may become colored due to the residual presence of heme group origination from hemoglobin present in whole blood samples as well as dried spot (DBS) samples. This can potentially cause the inhibition of PCR reactions and result in an uninterpretable test result. If using an Internal Control (IC) in the extraction process the IC could potentially be inhibited as well and invalidate test results.
Potential performance issue on strain categorization.
False susceptible results
Fulvestrant cross reacts with the VIDAS Estradiol II immunoassay and may cause falsely elevated estradiol results in patients treated with Fulvestrant.
Problem with colored eluates for whole blood extractions
Product Stability issues: The current shelf-life claims of the ETEST products are not supported by internal testing.
Product Stability issues: The current shelf-life claims of the ETEST products are not supported by internal testing.
Product Stability issues: The current shelf-life claims of the ETEST products are not supported by internal testing.
Product Stability issues: The current shelf-life claims of the ETEST products are not supported by internal testing.
Product Stability issues: The current shelf-life claims of the ETEST products are not supported by internal testing.
Product Stability issues: The current shelf-life claims of the ETEST products are not supported by internal testing.
Product Stability issues: The current shelf-life claims of the ETEST products are not supported by internal testing.
Product Stability issues: The current shelf-life claims of the ETEST products are not supported by internal testing.
Product Stability issues: The current shelf-life claims of the ETEST products are not supported by internal testing.
Product Stability issues: The current shelf-life claims of the ETEST products are not supported by internal testing.
Product Stability issues: The current shelf-life claims of the ETEST products are not supported by internal testing.
Product Stability issues: The current shelf-life claims of the ETEST products are not supported by internal testing.
Potential performance issues. False Susceptible result instead of Intermediate and False Intermediate result with certain methods.
During development of the VIDAS 3 software version 1.2, some anomalies have been identified and observed to be already present in the current software version VIDAS 3 version 1.1.4. available in the field.
A drift of the performance with the BK test (BK virus, worst case application) was observed for some silica batches of Magnetic Silica (MagSil). This is the same issue as in recall Z-2342-2016.
A drift of the performance with the BK test (BK virus, worst case application) was observed for some silica batches of Magnetic Silica (MagSil). This is the same issue as in recall Z-2342-2016.
Several customer complaints about amplification performance issues when using different batches of MagSil with the NucliSENS easyMAG extraction platform.
Discrepant identification results related to API identification strips. These discrepant identification results are due to false negative results on the tests of the strips linked to the ZYM B reagent.
QC results were out of range resulting in false resistant strains.
Customer complaints about not repeatable results below the detection limit (<45 ng/mL). Therefore false negatives are being reported for results around the medical decision point of 500 ng/mL that initially tested at <45 ng/mL.
Product is not approved or authorized for distribution in the US.
bioMerieux identified a visual defect and activity issue on the ZYM B reagent (REF 70493) and FB reagent (REF 70562). The activity issue lead to a false negative result of some Rapid ID 32 strips and API biochemical tests using the ZYM B reagent or FB reagent
bioMerieux identified a visual defect and activity issue on the ZYM B reagent (REF 70493) and FB reagent (REF 70562). The activity issue lead to a false negative result of some Rapid ID 32 strips and API biochemical tests using the ZYM B reagent or FB reagent
bioMerieux identified a visual defect and activity issue on the ZYM B reagent (REF 70493) and FB reagent (REF 70562). The activity issue lead to a false negative result of some Rapid ID 32 strips and API biochemical tests using the ZYM B reagent or FB reagent
bioMerieux identified a visual defect and activity issue on the ZYM B reagent (REF 70493) and FB reagent (REF 70562). The activity issue lead to a false negative result of some Rapid ID 32 strips and API biochemical tests using the ZYM B reagent or FB reagent